Status:
COMPLETED
To Examine the Lung When People With Diabetes Take an Inhaled Form of Insulin, Compared to Subcutaneous Insulin.
Lead Sponsor:
Pfizer
Collaborating Sponsors:
Sanofi
Conditions:
Diabetes Mellitus, Type 2
Eligibility:
All Genders
30-55 years
Phase:
PHASE2
Brief Summary
To examine the lung when people with diabetes take an inhaled form of insulin, compared to subcutaneous insulin.
Eligibility Criteria
Inclusion
- Type 2 Diabetes Mellitus
- Normal lung function
Exclusion
- Smokers
Key Trial Info
Start Date :
November 1 2004
Trial Type :
INTERVENTIONAL
End Date :
December 1 2006
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00143338
Start Date
November 1 2004
End Date
December 1 2006
Last Update
February 12 2008
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Fresno, California, United States
2
Pfizer Investigational Site
San Antonio, Texas, United States